Indivior Pharmaceuticals (INDV) EV to EBITDA (2024 - 2026)

Indivior Pharmaceuticals has reported EV to EBITDA for 3 years, with the latest figure at 28.88 in Q2 2026.

• On a quarterly basis, EV to EBITDA rose 56.42% year-over-year to 28.88 in Q2 2026; TTM through Jun 2026 was 10.97, a 80.82% increase from a year earlier, with the FY2025 full-year figure at 16.38, down 49.36% from the prior year.
• EV to EBITDA was 28.88 for Q2 2026 at Indivior Pharmaceuticals, up from 25.85 in the prior quarter.
• The five-year high for EV to EBITDA was 59.66 in Q3 2025, with the low at 18.44 in Q2 2024.
• Average EV to EBITDA over 3 years is 28.21, with a median of 27.8 recorded in 2024.
• The largest YoY upside for EV to EBITDA was 200.09% in 2025 against a maximum downside of 68.17% in 2025.
• Over 3 years, EV to EBITDA stood at 26.73 in 2024, then jumped by 98.27% to 52.99 in 2025, then tumbled by 45.51% to 28.88 in 2026.
• The last three EV to EBITDA figures came in at 28.88 (Q2 2026), 25.85 (Q1 2026), and 52.99 (Q4 2025), per Business Quant data.